Rlf Inhibitors
Rlf inhibitors are a class of chemical compounds designed to specifically inhibit the activity of Rlf, a transcription factor involved in the regulation of gene expression and cellular differentiation. Rlf, or "Rearranged L-myc Fusion" protein, is a key player in controlling the expression of genes that govern important cellular processes such as cell cycle regulation, differentiation, and proliferation. As a transcription factor, Rlf binds to specific DNA sequences, recruiting other co-factors and components of the transcriptional machinery to regulate the transcription of target genes. Inhibitors of Rlf disrupt its ability to interact with DNA or other transcriptional co-regulators, altering gene expression and impacting cellular pathways that rely on its regulatory functions.
The development of Rlf inhibitors focuses on understanding the structural features of Rlf that are critical for its activity, particularly its DNA-binding domains and interaction surfaces with other regulatory proteins. These inhibitors typically target the protein's ability to bind to specific promoter regions or interfere with the recruitment of necessary co-factors, thereby preventing it from activating or repressing the transcription of target genes. Researchers use structural biology techniques, such as molecular modeling and X-ray crystallography, to identify key binding sites on Rlf and to design inhibitors that can selectively block its activity. Specificity is crucial, as Rlf is part of a larger network of transcription factors, many of which share structural similarities. By selectively inhibiting Rlf, these compounds provide a means to study the transcriptional regulation of genes under its control, offering insights into how Rlf influences gene networks that contribute to cellular differentiation, growth, and development.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent protein kinase inhibitor that can inhibit a variety of protein kinases. Inhibition of these kinases can disrupt downstream signaling pathways necessary for the activity and function of Rearranged L-myc fusion gene protein. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is an inhibitor of PI3K, which is involved in signaling pathways that could lead to the activation of proteins downstream or in complex with the Rearranged L-myc fusion gene protein, inhibiting the functional activity of the protein. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a PI3K inhibitor that can inhibit signaling pathways, leading to the inhibition of downstream proteins that may work in concert with the Rearranged L-myc fusion gene protein, thus inhibiting its functional activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a key protein in cell growth and proliferation pathways. The inhibition of mTOR can suppress the pathways that are necessary for the functional activity of Rearranged L-myc fusion gene protein. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a MEK inhibitor which can block the MAPK/ERK pathway, potentially leading to the inhibition of signaling cascades that involve the Rearranged L-myc fusion gene protein, thereby inhibiting its function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that can inhibit the JNK signaling pathway, which may be involved in the functional regulation of the Rearranged L-myc fusion gene protein, leading to its inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor and can block the p38 signaling pathway that could be important for the functional activity of the Rearranged L-myc fusion gene protein, resulting in its inhibition. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2 and by inhibiting these kinases, it can disrupt the MAPK/ERK pathway that may interact with or regulate the Rearranged L-myc fusion gene protein, leading to the inhibition of its functional activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can lead to the accumulation of proteins destined for degradation. This accumulation can disrupt the cellular environment and inhibit the functional activity of proteins in the same pathways as Rearranged L-myc fusion gene protein. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src-family tyrosine kinase inhibitor, and by inhibiting these kinases, it can inhibit signaling pathways that regulate the activity and function of proteins associated with Rearranged L-myc fusion gene protein. | ||||||